Bemotrizinol: The 25-Year Overnight Sensation

A Molecule Older Than Your Skincare Routine

Every few years a skincare ingredient gets called "revolutionary" by people who have never read a toxicology table. This is not one of those stories. The ingredient making headlines this spring, bemotrizinol, has been in sunscreens in France, Japan, and Australia since the year 2000. It is not new. It is not experimental. Your cousin in Lisbon has been wearing it for two decades.⁷

What is new is the address. On December 11, 2025, the U.S. Food and Drug Administration issued a proposed order to add bemotrizinol to the short list of ultraviolet filters Americans are allowed to buy over the counter.¹ If that order is finalized this summer, it will be the first new UV filter the FDA has cleared for the U.S. market since 1999. The last time America got a new sunscreen ingredient, people were worried about Y2K.⁸

The press coverage has been euphoric and, in places, careless. Headlines promise that "European sunscreen is finally coming," as if you will be able to grab a bottle before Memorial Day. You will not. So let me do what The Corneum does: separate the genuinely good news, of which there is plenty, from the timeline fiction.

Here is the honest summary before the details. The chemistry is excellent. The global track record is long. The safety data the FDA finally received is reassuring. And none of that changes the fact that what exists today is a proposal, open for public comment, with a final decision expected around June 2026 and actual products realistically arriving in late 2026.⁹ Good ingredient. Slow government. Let's get into why.

What a Sunscreen Filter Is Actually For

Sunlight that reaches your skin comes in two flavors that matter here. UVB is the shorter wavelength that burns you and drives most skin cancers. UVA is the longer wavelength that penetrates deeper, drives photoaging, and contributes to cancer too. A good sunscreen has to block both. The American problem, for 25 years, has been UVA.¹¹

Bemotrizinol, known to chemists by the tongue-twister bis-ethylhexyloxyphenol methoxyphenyl triazine, is unusual because a single molecule absorbs across both bands. It has two absorption peaks: one near 310 nanometers in the UVB range, and one near 340 nanometers deep in UVA.⁷ Most filters cover one neighborhood. This one covers the whole street.

The second thing it does well is survive. Avobenzone, the main UVA filter Americans already have, is notoriously photo-unstable. It begins breaking down within an hour of sun exposure unless it is paired with a stabilizer, which is the molecular equivalent of hiring a bodyguard for your bodyguard. Bemotrizinol is the opposite. Reports describe roughly 98 percent of it remaining intact after fifty minimal-erythema doses of irradiation.⁷ It is so stable that formulators use it to protect other filters, propping up avobenzone and octinoxate so they last longer in the same bottle.²

That combination, broad coverage plus durability, is why dermatologists in Sydney and Seoul have treated bemotrizinol as a workhorse for two decades. It is not a marketing molecule. It is an engineering one.

One more piece of chemistry matters for the safety story. Bemotrizinol is a large, oily molecule, with a molecular weight around 629 daltons. The rough rule of thumb in dermatology is that molecules above 500 daltons struggle to cross the skin barrier in meaningful amounts. Bemotrizinol's size is part of why it tends to stay on the surface rather than slipping into your bloodstream, a fact that turns out to be the entire reason the FDA finally moved.²

The Data the FDA Spent a Decade Demanding

To understand why this took so long, you have to understand what the FDA was actually worried about. Not whether bemotrizinol blocks UV rays; that was never in question. The agency wanted to know how much of it ends up inside you, and whether that matters. In 2019 and 2020 the FDA ran its own studies on the sunscreen filters Americans already use, and the results were uncomfortable.⁶

That 0.5 nanograms-per-milliliter line is the key to the whole saga. It is not a danger threshold. It is a screening trigger: cross it, and the FDA wants a full safety workup before calling an ingredient generally recognized as safe and effective. The sponsor of bemotrizinol, the Swiss-Dutch firm dsm-firmenich, had to prove its molecule behaved better. So it ran the study the agency wanted.^3,5

Beyond absorption, the FDA's own December 2025 scientific review walked through the rest of the file. Two adequate and well-controlled SPF studies confirmed efficacy at the proposed 6 percent maximum, alone and in combination with other filters.² Repeat-exposure testing showed no irritation, sensitization, photoallergy, or phototoxicity. Old worries that UV filters might act as endocrine disruptors did not stick to this one: bemotrizinol was negative in both estrogen- and androgen-receptor binding assays. The agency tentatively concluded no signals for carcinogenicity or reproductive toxicity.²

Take the body of evidence together and the picture is genuinely good. The efficacy case is settled by twenty years of global use and confirmatory SPF data. The safety question that stalled approval for a decade now has a clean, on-protocol answer. That is a stronger evidence base than most things I review here. It is also, as we are about to see, attached to a regulatory process that moves like cold honey.

Why America Got Stuck in 1999

If the molecule is this good and this old, why did it take 25 years? The answer is a bureaucratic saga that deserves its own documentary. Bemotrizinol's first U.S. application dates to the late 1990s, the Ciba chemicals era. It then sat in a queue, along with seven or so other filters, while the FDA and applicants effectively ghosted one another for years.⁸

Congress tried to break the logjam with the Sunscreen Innovation Act of 2014, which created a faster review pathway for ingredients with a long history of use abroad.¹⁵ It did not work as hoped. In proposed rules in 2019, reaffirmed in 2021, the FDA declined to declare the backlog of organic filters generally recognized as safe and effective, citing missing modern human-absorption data. The agency had moved the goalposts to a reasonable but expensive new location, and someone had to pay to reach them.⁶

That someone was dsm-firmenich, which markets bemotrizinol as PARSOL Shield. By industry accounting, the company spent on the order of 18 million dollars and roughly two decades shepherding this single ingredient through the U.S. system, including the pivotal maximal-usage trial and a full nonclinical battery.⁸ When people ask why your American sunscreen feels a generation behind a Korean one, this is the answer: the cost and uncertainty of U.S. approval are high enough that most companies simply do not bother.

The reform that finally helped was procedural. Under the post-CARES Act monograph system, a sponsor can file a Tier 1 order request with a complete data package and get a binding administrative decision, rather than waiting for a sprawling rulemaking to conclude.¹³ That is the mechanism behind the December 2025 proposed order, and it is why, for the first time in a quarter century, the pipeline actually produced something.

Here is the part the celebratory headlines skip. Bemotrizinol would be only the third UV filter deemed GRASE under the FDA's modern standard, joining zinc oxide and titanium dioxide. The dozen-plus chemical filters already in your current sunscreen, the avobenzones and octinoxates, still sit in regulatory limbo, grandfathered in but not formally blessed. Approving one new filter does not suddenly make the U.S. sunscreen aisle equal to Europe's multi-filter formulations. It closes one gap, not all of them.²

What the Excitement Leaves Out

I want this approval to go through. The UVA gap in American sunscreens is real, and bemotrizinol is a sober, well-documented way to start closing it. But sober enthusiasm requires reading the footnotes, so here are four of them.

There is also the environmental footnote, repeated everywhere as settled fact. Bemotrizinol is widely described as more reef-friendly than oxybenzone, and that is plausible, because it is large, oily, and poorly water-soluble. But it does turn up in wastewater and surface water as an emerging pollutant at low concentrations, and the long-term bioaccumulation picture is thinner than the confident "reef-safe" labels imply.¹² I would file this under "probably better, not proven benign."

And the oldest truth in my field still applies. The best filter in the world does nothing if you apply a thin smear once and skip the reapplication. Bemotrizinol does not fix the human behavior that undermines every sunscreen ever made. It just gives the conscientious among you a better tool to be conscientious with.¹⁴